NEW YORK, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Eyenovia Inc. ("Eyenovia") EYEN, a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced that Dr. Sean Ianchulev, Eyenovia's Chief Executive Officer is scheduled to present at the 30th Annual ROTH Conference taking place on March 11-13, 2018 at The Ritz-Carlton in Dana Point, California.
Details of the presentation are below:
Event: 30th Annual ROTH Conference
Date: Monday, March 12, 2018
Time: 12:30pm PT / 3:30pm ET
A live webcast of the presentation may be accessed at http://wsw.com/webcast/roth32/eyen/ or on the Company's website at http://eyenoviabio.com. The webcast will be archived for 90 days following the live presentation on the Company's website.
About Eyenovia
Eyenovia is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for micro-therapeutics. Eyenovia's pipeline is currently focused on the late-stage development of micro-therapeutics for glaucoma and other eye diseases.
Company Contact:
Eyenovia Inc.
John Gandolfo
Chief Financial Officer
jgandolfo@eyenoviabio.com
Investor Contact:
Lee Roth / Tram Bui
The Ruth Group
Phone: 646-536-7012/7035
E-mail: lroth@theruthgroup.com/tbui@theruthgroup.com
Media Contact:
The Ruth Group
Kirsten Thomas
508-280-6592
kthomas@theruthgroup.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.